Results 111 to 120 of about 35,471,860 (258)

Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. [PDF]

Cancer Immunol Immunother, 2021
Suliman AM, Bek SA, Elkhatim MS, Husain AA, Mismar AY, Eldean MZS, Lengyel Z, Elazzazy S, Rasul KI, Omar NE.   +9 more
europepmc   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Deciphering the role of signal regulatory protein α in immunotherapy for solid tumors

Frontiers in Immunology
Therapies targeting immune checkpoints like programmed death receptor-1 and programmed death ligand-1 have demonstrated remarkable effectiveness in combating cancer.
Yulong Zhou, Xiyang Tang, Weiguang Du, Chen Shu, Chen Shu, Xiaolong Yan, Nan Ma, Jinbo Zhao   +7 more
doaj   +1 more source

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors. [PDF]

Cancer Immunol Immunother, 2021
Papadopoulos KP, Lakhani N, Falchook GS, Riley G, Baeck J, Brown KS, Gordon G, Le L, Wang JS.   +8 more
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Age-related changes of apoptotic cell death in human lymphocytes [PDF]

, 2006
Apoptosis seems to be involved in immunosenescence associated with aging. Moreover, in lymphocytes (PBL) of patients with Alzheimer's disease, an increased susceptibility to the apoptotic pathway has been described possibly due to impaired protection of ...
Schindowski, Katharina, Leutner, Silke, Eckert, Anne, Müller, Walter E.   +3 more
core  

Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1

JAAD Case Reports, 2021
Claire J. Wiggins, BS, Van K. Morris, MD, Natasha K. Klimas, MD, Priyadharsini Nagarajan, MD, PhD, Jonathan L. Curry, MD, Kristen N. Richards, MD   +5 more
doaj   +1 more source

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial

Cancer Medicine
Background The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis.
Qinglian Tang, Xinke Zhang, Xiaojun Zhu, Huaiyuan Xu, Guohui Song, Jinchang Lu, Hao Wu, Chuangzhong Deng, Fei Ai, Yingchun Zhang, Jin Wang   +10 more
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

Cancer Medicine, 2019
Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously ...
Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura   +20 more
doaj   +1 more source